Skip to content

News

Single-Cell Discovery-Thumbnail

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunology.
Read More

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solutions, announce a strategic partnership. The companies will create a joint biomarker discovery workflow, leveraging Lexogen’s new single-cell RNA sequencing platform LUTHOR™ and Scailyte’s AI-driven analytics platform ScaiVision™.
Read More

Scailyte Quarterly Update, June 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Read More

Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Michael Brenner MD, Elizabeth Fay Brigham Professor of Medicine at Harvard Medical School, has joined Scailyte as an advisor to the Board of Directors.
Read More

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection May 21 2021 ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG. Recent News
Read More
Making groundbreaking discoveries require collaborations and joint-ventures.